G
Geoffrey W. Henson
Researcher at Johnson Matthey
Publications - 59
Citations - 5391
Geoffrey W. Henson is an academic researcher from Johnson Matthey. The author has contributed to research in topics: Nucleoside & Pharmacokinetics. The author has an hindex of 28, co-authored 59 publications receiving 5282 citations. Previous affiliations of Geoffrey W. Henson include Rega Institute for Medical Research & Cardiff University.
Papers
More filters
Journal ArticleDOI
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor
G A Donzella,Dominique Schols,Steven Lin,José A. Esté,Kirsten A. Nagashima,Paul J. Maddon,Graham P. Allaway,Thomas P. Sakmar,Geoffrey W. Henson,E. De Clercq,John P. Moore +10 more
TL;DR: The bicyclam AMD3100 blocks HIV-1 entry and membrane fusion via the CXCR4 co-receptor, but not via CCR5, and development of small molecule inhibitors of HIV- 1 entry is feasible.
Journal ArticleDOI
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.
W. Conrad Liles,W. Conrad Liles,Hal E. Broxmeyer,Hal E. Broxmeyer,Elin Rodger,Elin Rodger,Brent L. Wood,Brent L. Wood,Kai Hübel,Kai Hübel,Scott Cooper,Scott Cooper,Giao Hangoc,Giao Hangoc,Gary Bridger,Gary Bridger,Geoffrey W. Henson,Geoffrey W. Henson,Gary Calandra,Gary Calandra,David C. Dale +20 more
TL;DR: Findings suggest potential clinical application of AMD3100 for CD34+ cell mobilization and collection for hematopoietic stem cell transplantation.
Journal ArticleDOI
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
TL;DR: The bicyclams are, to the authors' knowledge, the first low molecular weight anti-HIV agents shown to act as potent and selective CXCR4 antagonists.
Journal ArticleDOI
Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers
Craig W. Hendrix,Charles Flexner,Ronald Trevor Macfarland,Christen Giandomenico,Edward J. Fuchs,Ella Redpath,Gary Bridger,Geoffrey W. Henson +7 more
TL;DR: ABSTRACT AMD-3100, a bicyclam, is a novel agent that uniquely inhibits the entry of human immunodeficiency virus type 1 (HIV-1) into CD4+ T cells via selective blockade of the chemokine CXCR-4 receptor.
Journal ArticleDOI
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
Craig W. Hendrix,Ann C. Collier,Michael M. Lederman,Dominique Schols,Richard B. Pollard,Stephen J. Brown,J. Brooks Jackson,Robert W. Coombs,Marshall J. Glesby,Charles Flexner,Gary Bridger,Karin Badel,Ronald Trevor Macfarland,Geoffrey W. Henson,Gary Calandra +14 more
TL;DR: Given these results, AMD3100 is not being further developed for ARV therapy, but development continues for stem cell mobilization.